PTN Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States...

Stats
Dagens volum	553 607
Gjennomsnittsvolum	643 506
Markedsverdi	34.05M
EPS	$-0.560 ( 2024-02-15 )
Neste inntjeningsdato	( $-0.660 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.710
ATR14	$0.0180 (0.86%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Deveer Robert K Jr	Buy	6 000	Common Stock
2024-03-06	Deveer Robert K Jr	Sell	1 685	Common Stock
2024-03-06	Deveer Robert K Jr	Sell	7 286	Common Stock
2024-03-06	Deveer Robert K Jr	Sell	200	Common Stock
2024-03-06	Deveer Robert K Jr	Sell	1 808	Common Stock

INSIDER POWER
47.51
Last 100 transactions
Buy: 594 391 \| Sell: 320 931

Volum Korrelasjon

Lang: -0.09 (neutral)

Kort: -0.59 (weak negative)

Signal:(46.047) Neutral

Palatin Technologies Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Palatin Technologies Inc Korrelasjon - Valuta/Råvare

-0.17
( neutral )

0.35
( neutral )

0.00
( neutral )

0.52
( weak )

Palatin Technologies Inc Økonomi

Annual	2023
Omsetning:	$4.85M
Bruttogevinst:	$4.44M (91.38 %)
EPS:	$-2.53

FY	2023
Omsetning:	$4.85M
Bruttogevinst:	$4.44M (91.38 %)
EPS:	$-2.53

FY	2022
Omsetning:	$1.47M
Bruttogevinst:	$1.25M (85.19 %)
EPS:	$-3.75

FY	2021
Omsetning:	$-188 597
Bruttogevinst:	$-336 437 (-178.39 %)
EPS:	$-3.55

Financial Reports:

No articles found.

Palatin Technologies Inc

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.